Posted by Michael Wonder on 10 Dec 2018
Proposal to open access to atomoxetine and change funded brand
10 December 2018 - PHARMAC is proposing to remove all funding restrictions from all presentations of atomoxetine, and change the funded brand of atomoxetine from Strattera to a brand supplied by Generic Partners Limited.
The Generic Partners brand of atomoxetine would be listed from 1 July 2019, and the community and hospital funding restrictions on atomoxetine would be removed at the same time. There would then be a transition period, detailed below, after which Strattera would be delisted.
The Generic Partners brand of atomoxetine would be awarded sole supply from 1 December 2019 until 30 June 2022, meaning that it would be the only funded brand of atomoxetine during this time.
